Genomic Health, Inc. (NASDAQ:GHDX) insider Steven Shak sold 1,500 shares of the firm’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $78.18, for a total transaction of $117,270.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Steven Shak also recently made the following trade(s):
- On Monday, September 10th, Steven Shak sold 5,500 shares of Genomic Health stock. The stock was sold at an average price of $63.05, for a total transaction of $346,775.00.
Shares of GHDX traded up $1.53 during mid-day trading on Thursday, hitting $75.50. The company had a trading volume of 475,170 shares, compared to its average volume of 294,643. Genomic Health, Inc. has a 1-year low of $26.54 and a 1-year high of $92.18. The stock has a market capitalization of $2.67 billion, a PE ratio of 7,550.00 and a beta of 0.40.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Globeflex Capital L P acquired a new stake in shares of Genomic Health in the second quarter worth approximately $116,000. Sun Life Financial INC acquired a new stake in shares of Genomic Health in the second quarter worth approximately $122,000. Pacer Advisors Inc. acquired a new stake in shares of Genomic Health in the third quarter worth approximately $171,000. Trexquant Investment LP acquired a new stake in shares of Genomic Health in the third quarter worth approximately $202,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Genomic Health in the second quarter worth approximately $162,000. 89.21% of the stock is currently owned by institutional investors and hedge funds.
GHDX has been the topic of several analyst reports. Raymond James initiated coverage on shares of Genomic Health in a research note on Tuesday, October 23rd. They set a “market perform” rating on the stock. Zacks Investment Research reaffirmed a “hold” rating on shares of Genomic Health in a research note on Tuesday, November 13th. BidaskClub raised shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 30th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $82.00 price target (up from $70.00) on shares of Genomic Health in a research note on Wednesday, November 7th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $48.33.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Further Reading: Average Daily Trade Volume Explained
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.